Jim Adelizzi co-wrote this blog post with Pavankumar Anne.
The excitement behind precision medicine in oncology is impossible to ignore. Genomic profiling has enabled the greatest growth in precision medicine in oncology, and today there are 80-plus FDA-approved treatment options indicated for specific genetic markers. Innovations in next-generation sequencing (NGS) technology have further enabled advances in genomic profiling by increasing the speed, accuracy and affordability of sequencing. With this innovation comes a variety of options for testing:
The promise of precision medicine—tailoring treatments to genetic changes in each cancer patient—is very exciting. Advances in science and genomic testing have helped speed up the pace of precision medicine and brought several innovative targeted therapies and immunotherapies to market already. Precision medicine was the theme at last year’s American Society of Clinical Oncology (ASCO) annual meeting, with more than 500 abstracts involving genomic testing. It’s safe to say that precision medicine has become a buzzy topic. However, at this year’s ASCO event, we continued to hear that there are significant challenges to the widespread adoption of precision medicine. What will it take to bring the promise of precision medicine to more patients and embed it in routine care?
American Society of Clinical Oncology,